<DOC>
	<DOCNO>NCT01346475</DOCNO>
	<brief_summary>On 13 August 2008 , trial submit ClinicalTrials.gov modification NCT00362297 . On 28 April 2011 , two record split administrative purpose trial give unique study record . Please refer `` History Changes '' post NCT00362297 detail summary modification . The purpose research study evaluate effectiveness high-dose valacyclovir compare daily valacyclovir reduction asymptomatic HSV-2 genital shed person genital herpes . The study enroll men woman 18 year old , test positive HSV-2 ( blood test ) first outbreak HSV-2 within past 6 month least 4 genital herpes outbreak past year . Participants must HIV negative willing stop take suppressive therapy HSV one week wash period . ( Females : You must pregnant breast-feeding ) . Both men woman ask use effective form birth control . Involvement study last 11-weeks ask visit clinic every 2-weeks . At visit , give medication take daily ( either daily valacyclovir high dose valacyclovir ; receive medication point study ) . We ask give blood sample liver , kidney blood count test visit . There total 8 study visit visit last approximately 30 minute . We ask complete daily symptom diary collect daily home swab 4-times day , everyday study . Each daily home swab take less 3 minute perform .</brief_summary>
	<brief_title>Randomized Trial Evaluate Suppressive Effect High-Dose Valacyclovir Versus Once-Daily Valacyclovir Persons With HSV-2</brief_title>
	<detailed_description>Screening Assessment Patients assess eligibility enter study screen visit . After sign informed consent undergo medical history follow information record Case Report Form ( CRF ) : - Demographic Data : Date birth , sex , marital status , education race - Previous antiviral medication take - History sexually transmit infection sexual history . - Women childbearing potential undergo urine pregnancy test . Serologic sample HSV-2 HIV obtain . Part blood sample also use safety lab . Start Study Visit ( Day 0 ) Day 14 , 28 , 35 , 42 , 56 , 70 , 77 Follow-Up Visits . Eligible patient return clinic give study drug patient diary card record concomitant medication , sign symptom , adverse experience . The investigator instruct patient daily home viral sample collection , take study drug , complete diary card . The patient instruct return clinic 2 week , +/- 2 day . Medication compliance assess visit use pill count . Safety labs perform day 14 , 28 , 35 , 56 , 70 77 . Crossover Study Visit Prior To Washout Period ( Day 35-41 ) Participants give study drug placebo 7-day washout period . Participants require obtain swabs washout period . Daily Home Viral Sample Collection Participants collect swabs genital mucosa four time per day store sample PCR medium preprinted label . Women swab cervicovaginal , vulvar perianal area , men swab penile perianal . Every two week , return sample Virology Research Clinic present additional study drug assessment . Final Study Visit ( Day 77 ) At final study visit Day 77 premature discontinuation , investigator perform activity regular study visit , exception dispensation study drug .</detailed_description>
	<mesh_term>Herpes Genitalis</mesh_term>
	<mesh_term>Valacyclovir</mesh_term>
	<mesh_term>Acyclovir</mesh_term>
	<criteria>18 year old ; HSV2 seropositive Western Blot ; receive drug know antiHSV2 activity study duration ; history primary genital herpes infection within past 6 month OR history 4 HSV recurrence per year past year OR 4 recurrence per year prior initiation suppressive antiviral therapy ; shed HSV2 genital mucosa &gt; 25 % day shed session perform VRC within last 2 year . able comply study protocol ; woman child bear potential sexually active men must use medically accept method contraception judge investigator ; woman childbearing potential must negative pregnancy test ( urine ) screen visit ; general good health , without serious medical condition specifically normal renal hepatic function , determine patient 's medical history ; plan remain resident area study center duration study participation ; HIV seronegative . hypersensitivity acyclovir valacyclovir ; pregnant woman ; HIV positive immunosuppressed state , include chronic steroid use . Intermittent nasal topical steroid acceptable</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>